Literature DB >> 322709

Purification and structural analysis of the fourth component of human complement.

C Bolotin, S Morris, B Tack, J Prahl.   

Abstract

The fourth component of human complement (C4) has been purified in 20% yield from fresh plasma using as starting material the 5-12% poly(ethylene glycol) precipitate which had been depleted of plasminogen by an affinity adsorbent. Sequential ion-exchange chromatography on diethylaminoethylcellulose, QAE-Sephadex, and DEAE-Bio-Gel A resulted in C4 homogeneous by immunological criteria and by polyacrylamide gel electrophoresis, the last chromatographic step achieving separation of native from inactivated C4. Reduction with 20 mM dithiothreitol for 2 h at 37 degrees C in 0.25 M 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride, pH 8.6, effected cleavage of the interchain disulfide bonds. A three-chain structure for C4 was confirmed, and molecular weight estimates of 93 000 +/- 9300, 75 000 +/- 7500, and 30 000 +/- 3000 determined for the alpha, beta, and gamma chains, respectively. The effects of known inactivators of C4 upon the chains of C4 were investigated, confirming that the inactivations by C1s and trypsin were accompanied by the fragmentation of the alpha chain. Inactivation of C4 by hydrazine, on the other hand, produced no detectable change in chain size. Separation of the chains was accomplished by gel filtration in the presence of 1 M acetic acid. Amino acid compositions of native C4 and the constitutive chains have been performed, and N-terminal sequences of the latter established by automated Edman degradation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 322709     DOI: 10.1021/bi00628a039

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  35 in total

1.  Inhibition of human complement by beta-glycyrrhetinic acid.

Authors:  B H Kroes; C J Beukelman; A J van den Berg; G J Wolbink; H van Dijk; R P Labadie
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

2.  Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.

Authors:  J A Charlesworth; P W Peake; J Golding; J D Mackie; B A Pussell; V Timmermans; D Wakefield
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

3.  Prevention of immune precipitation by purified components of the alternative pathway.

Authors:  J K Naama; E Holme; E Hamilton; K Whaley
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

4.  Studies on murine Ss protein: demonstration that S region encodes structural gene for fourth component of complement.

Authors:  M C Carroll; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  The isolation and characterization of bovine C4a, an activation fragment of the fourth component of complement.

Authors:  N A Booth; R D Campbell; M A Smith; J E Fothergill
Journal:  Biochem J       Date:  1979-12-01       Impact factor: 3.857

6.  The purification and characterization of bovine C4, the fourth component of complement.

Authors:  N A Booth; R D Campbell; J E Fothergill
Journal:  Biochem J       Date:  1979-03-01       Impact factor: 3.857

7.  Amino acid sequence homologies and glycosylation differences between the fourth component of murine complement and sex-limited protein.

Authors:  D R Karp; K L Parker; D C Shreffler; C Slaughter; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

8.  Polymorphism of human erythrocyte C3b/C4b receptor.

Authors:  T R Dykman; J L Cole; K Iida; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

9.  C4a: the third anaphylatoxin of the human complement system.

Authors:  J P Gorski; T E Hugli; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

10.  The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.

Authors:  H Kitamura; M Tsuboi; K Nagaki
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.